Other programs

Vonafexor in HBV and HDV

In addition to its strong fibrolytic and anti-inflammatory effect, Vonafexor displays anti-viral properties against Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV).

ENYO Pharma has already conducted 5 clinical studies (3 phases I and 2 phases II) with Vonafexor for HBV indication. Click here for more information

• Radreau et al. (2016): Reciprocal regulation of Farnesoid X Receptor a activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. FASEB J. Radreau et al. (2016)
• Curtil et al. (2014): The metabolic sensors FXR, PGC-1, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J. Curtil et al. (2014)
• Ramière et al (2008): The metabolic sensors FXR, PGC-1, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J. Ramière et al (2008)

HDV is also addressed in preclinical studies.

Drug discovery platform

“There is a huge untapped goldmine of targets to be uncovered…” Jacky Vonderscher, CEO and co-founder of ENYO Pharma.

Our story began in 2014 when experts in virus-host protein interactions from the French Infectiology Research Center (Inserm) in Lyon, France and pharmaceutical industry executives specialized in drug development developed a unique drug discovery platform based on biomimetism inspired by viruses.

EYP002

EYP002 is a new first-in-class chemical series under lead optimization, initially developed using inhibition of influenza replication as a phenotypic assay. Molecules modulate the activity of a small family of mitochondrial proteins, the NEET proteins encoded by three CISD genes.